2. Search Result
Search Result
Results for "

SCID mice

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Peptides

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99588
    Stamulumab

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-149428
    AD4
    1 Publications Verification

    		 PROTACs Cancer
    AD4 is an artemisinin derivative that is a proteolytic targeting chimera (PROTAC) targeting PCLAF. AD4 can effectively degrade PCLAF in RS4;11 cells (IC50: 0.6 nM), thereby activating the p21/Rb axis and exerting anti-tumor activity. AD4 also prolonged survival of RS4;11-transplanted NOD/SCID mice, with in vivo efficacy .
    AD4
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    1 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-158421
    MS-L6

    		Oxidative Phosphorylation Mitochondrial Metabolism Cancer
    MS-L6 is a potent inhibitor of oxidative phosphorylation (OXPHOS) that can acts as electron transport chain complexes I (ETC-I) combining inhibition of NADH oxidation and uncoupling effect .
    MS-L6
  • HY-153066
    VLS-1272

    KIF18A-IN-7

    		 Kinesin Microtubule/Tubulin Apoptosis Cancer
    VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CIN High tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research .
    VLS-1272
  • HY-153065
    KIF18A-IN-6

    		Kinesin Microtubule/Tubulin Cancer
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity .
    KIF18A-IN-6
  • HY-W018723
    4-Aminobenzamidine dihydrochloride
    1 Publications Verification

    p-Aminobenzamidine dihydrochloride

    		 Ser/Thr Protease PAI-1 Cardiovascular Disease Cancer
    4-Aminobenzamidine (p-Aminobenzamidine) dihydrochloride is a strong trypsin inhibitor. 4-Aminobenzamidine dihydrochloride acts as an orally active urokinase type plasminogen activator (uPA) inhibitor (Ki=82 μM). 4-Aminobenzamidine dihydrochloride can be used for cardiovascular diseases and anti-tumor study .
    4-Aminobenzamidine dihydrochloride
  • HY-169240
    MX69-102

    		MDM-2/p53 Cancer
    MX69-102 (compound MX69-102) is an MDM-2/p53 inhibitor, inducing MDM2 degradation, resulting in p53 activation and cancer cell apoptosis. MX69-102 shows effective inhibition on xenografted human MDM2-overexpressing ALL in SCID mice. .
    MX69-102
  • HY-168270
    PROTAC ER Degrader-11

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-11 (Example 26-1) is a potent PROTAC ER degrader, with the IC50 of 0.66 nM. PROTAC ER Degrader-11 plays an important role in cancer research(Sturcture Note:(Blue: Cereblon ligand (HY-W797329), Black: linker (HY-W262798)；Pink: ER ligand (HY-168271)) .
    PROTAC ER Degrader-11
  • HY-P99595
    Sirtratumab vedotin

    AGS15E; ASG-15ME; 1vcMMAE

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .
    Sirtratumab vedotin
  • HY-158113
    CBPD-409

    		Histone Acetyltransferase PROTACs Cancer
    CBPD-409 is an orally active PROTAC degrader for CBP/p300, with DC50 of 0.2–0.4 nM. CBPD-409 exhibits antiproliferative effects in AR+ prostate cancer cell lines VCaP, LNCaP and 22Rv1, with IC50s of 1.2–2.0 nM. CBPD-409 exhibits antitumor efficacy (Red: CBP inhibitor GNE049 (HY-108435); Blue: CRBN/cullin 4A Thalidomide (HY-14658); Black: Linker) .
    CBPD-409
  • HY-164039
    Talorasib

    		Others Cancer
    Talorasib (compound 1-2) has antitumor activity .
    Talorasib
  • HY-114311
    FGFR1/DDR2 inhibitor 1
    1 Publications Verification

    		 FGFR Discoidin Domain Receptor Cancer
    FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .
    FGFR1/DDR2 inhibitor 1
  • HY-118748
    Suprafenacine

    SRF

    		 Microtubule/Tubulin Cancer
    Suprafenacine is a cell permeable, tubulin-destabilizing molecule which bind microtubules at the colchicine-binding site and inhibit polymerization. Suprafenacine can induce G2/M cell cycle arrest and apoptosis, and can be used for cancer research .
    Suprafenacine
  • HY-125858A
    MI-1061 TFA
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 TFA is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 TFA potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061 TFA
  • HY-125858
    MI-1061
    1 Publications Verification

    		 MDM-2/p53 E1/E2/E3 Enzyme Apoptosis Cancer
    MI-1061 is a potent, orally bioavailable, and chemically stable MDM2 (MDM2-p53 interaction) inhibitor (IC50=4.4 nM; Ki=0.16 nM). MI-1061 potently activates p53 and induces apoptosis in the SJSA-1 xenograft tumor tissue in mice. Anti-tumor activity .
    MI-1061
  • HY-P10301
    CXCL9(74-103)

    		CXCR Cancer
    CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .
    CXCL9(74-103)
  • HY-13846
    BM-1074

    		Bcl-2 Family Apoptosis Cancer
    BM-1074 is a potent and specific Bcl-2/Bcl-xL inhibitor with Ki values of < 1 nM and IC50 values of 1.8 nM and 6.9 nM for Bcl-2 and Bcl-xL, respectively. BM-1074 induces apoptosis, and exhibits antiproliferative activity against four small-cell lung cancer cell lines (H146, H1963, H187 and H1417) with IC50 values of 1-2 nM .
    BM-1074
  • HY-163483
    ELQ-598

    		Parasite Others
    ELQ-598, as a prodrug, is converted into the active drug ELQ-596 upon oral administration. ELQ-598 demonstrates potent parasitic growth inhibition capabilities (IC50= 37 nM). ELQ-598 also shows low toxicity towards human cells (IC50= 19 μM). ELQ-598 can be used for research into babesiosis .
    ELQ-598
  • HY-112417
    Ki11502

    		PDGFR FLT3 Apoptosis Akt PERK Bcl-2 Family Cardiovascular Disease Cancer
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis .
    Ki11502

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: